Yazar "Ozbek, E." seçeneğine göre listele

Listeleniyor 1 - 6 / 6
  • [ X ]
    Öğe
    Castleman's disease as cervical mass: a report of three cases and review of the literature
    (Cic Edizioni Int, 2009) Cakabay, B.; Akbulut, S.; Sezgin, A.; Gomceli, I.; Arikok, A. T.; Ozmen, C. Akgul; Ozbek, E.
    node hyperplasia involving lymphatic tissue in the neck, mediastinum, abdomen and other areas. Disease was described for the first time in 1956 by Castleman. The etiopathogenesis of the disease is unknown. The disorder can be classified into three histopathological types: hyalin-vascular, plasma-cell and mixed. We report three cases of the Castleman's disease (hyaline-vascular type) in three female patients with unilateral swelling of the neck. None of the patients developed any local or distant recurrence in postoperative follow-up.
  • [ X ]
    Öğe
    Comparison of tuberculin skin test and a specific T-cell-based test, T-Spot™.TB, for the diagnosis of latent tuberculosis infection
    (Sage Publications Ltd, 2007) Ozekinci, T.; Ozbek, E.; Celik, Y.
    There is substantial evidence that the detection of T cells specific for the proteins ESAT-6 and CFP-10 using the ex vivo enzyme-linked immunospot technique is a marked improvement on the existing tuberculin skin test (TST). This new technique, which detects,gamma-interferon-producing T cells, is now available as the commercial assay, T-Spot (TM).TB. We compared the T-Spot (TM).TB test with the TST for the diagnosis of latent tuberculosis infection (LTBI) in different groups of subjects. Significant accordance (85.7%) between the tests was found in subjects with active lung tuberculosis and in tuberculosis clinic and laboratory personnel (63.6%) but accordance was lowest and not significant amongst house contacts of tuberculosis patients (53.6%). We conclude that, in countries where vaccination is routinely performed, the T-Spot (TM).TB test is a useful diagnostic test for LTBI in highrisk groups when carried out either together with the TST and/or to confirm the TST result.
  • [ X ]
    Öğe
    HEPATITIS C VIRUS GENOTYPES ARE CHANGING IN THE SOUTHEAST OF TURKEY
    (Diagnosis Press Ltd, 2009) Ozbek, E.; Ozekinci, T.; Mese, S.; Atmaca, S.
    Hepatitis C virus (HCV) infection is a frequent cause of acute and chronic hepatitis, and may lead to the development of cirrhosis and subsequently hepatocellular carcinoma. It is estimated that about 150 to 200 million people have been in contact with HCV worldwide, and approximately 85% are chronically infected. HCV is a highly heterogenous virus. At least 6 genotypes and more than 50 subtypes marked with letters (e.g. 1a, 1b, 2a, 2b) of the virus, have been detected worldwide until now HCV genotype 1 was detected as the most common genotype in the studies also done in our country. The aim of this study is to determine the HCV genotypes and reveal the change in HCV genotypes in the South-Eastern region of Turkey. Between April 2007 and October 2008, the study evaluated serum samples of 74 patients (40 women) that were HCV RNA positive determined by polymerase chain reaction (PCR). HCV genotypes were determined with Inno-LIPA method. 5'non-coding region (5'NCR) of HCV-RNA was amplified by reverse transcriptase polymerase chain reaction (RT-PCR) and genotyped by line probes in Inno-LIPA assay. The genotype results of HCV in the serum samples were as follows: 87.8% genotype 1b, 4.1% genotype 1, 2.7%genotype 2, 2.7% genotype 3 and 2.7% genotype 3a. Genotype I was determined predominantly in a total of 68 (91.9%) patients.
  • [ X ]
    Öğe
    Hepatitis C virus genotypes are changing in the southeast of Turkey
    (Elsevier Science Bv, 2009) Ozbek, E.; Ozekinci, T.; Mese, S.; Atmaca, S.
    [Abstract Not Available]
  • [ X ]
    Öğe
    Lack of correlation between CRP and hepatitis B viral load in serum of patients with chronic HBV
    (W B Saunders Co Ltd, 2007) Gedik, M.; Ozekinci, T.; Ozbek, E.; Atmaca, S.; Yilmaz, S.
    [Abstract Not Available]
  • [ X ]
    Öğe
    Retrospective review of re-positive qPCR tests for SARS-CoV: do they indicate presence of reinfection?
    (Verduci Publisher, 2022) Temiz, H.; Ozbek, E.; Zeyrek, F. Yildiz
    OBJECTIVE: In 2019, the Coronavirus Disease 2019 (COVID-19) pandemic broke out, caused by the coronavirus called Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Reinfections can be observed with various respiratory viruses, including human coronaviruses. Moreover, they may result from weak or waning initial immune response, reinfection with another genotype/subtype. or the rapid antigenic changes in the virus. The aim of this study was to investigate the likelihood of reinfection in COVID-19 patients that had a positive qPCR test result at least 60 days after a negative test result in patients that were confirmed with COVID-19 on qPCR. MATERIALS AND METHODS: The quantitative polymerase chain reaction (qPCR) results of a total of 105,000 samples that had been obtained between April 1, 2020, and February 1, 2021, in two separate authorized laboratories were retrospectively analyzed. 22 samples from 11 patients included in the study, qPCR tests were repeated for each sample using the Rotorgene Q PCR system with Diagnovital SARS-CoV-2 (RTA Labs, Turkey) Real-Time PCR kits. Positive samples were screened for 8.1.1.7 and E484K mutations using the qPCR method on the Rotorgene Q PCR system with Bio-Speedy SARS-CoV-2 Variant Plus kits (Bioeksen Technology, Turkey). RESULTS: The 105,000 individuals comprised 55,614 men and 49,386 women. In the qPCR test, 14,511 (13.82%) individuals were found to be positive for SARS-CoV-2. Of these, 11 (0.076%) patients were included in the study based on the inclusion criteria. Accordingly. the risk of reinfection was calculated as 0.076% (95% confidence interval [CI]: 0.056%-0.096%) and the incidence was 1.04 per 10,000 population (95% CI: 0.62-1.38 per 10,000). No patient was admitted to the intensive care unit or died during both episodes. Moreover, no B.1.1.7 or E484K mutation was detected in any patient. CONCLUSIONS: The high frequency of COVID-19 infection poses serious risks for the development of new variants and the currently used vaccines are likely to lose their efficacy against new variants. To reduce these risks and to be successful in the fight against the pandemic, we suggest compliance with personal protective measures as well as rapid and widespread application of vaccination not only in developed countries but also in the whole world and the modification of currently used vaccines in such a way to fight against newly emerged variants.